In vivo antitumor activity of the hypoxanthine derivatives ST 789 and ST 689.
De Simone
C
C
Clinica Medica, L'Aquila, Italy.
Famularo
G
G
Foresta
P
P
Albertoni
C
C
Arrigoni Martelli
E
E
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007042:Hypoxanthines / Q000494:pharmacology*; D015850:Interleukin-6 / Q000502:physiology; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000473:pathology; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007042:Hypoxanthines; D015850:Interleukin-6; C054420:PCF 39; C082840:ST 689; D001120:Arginine